Canaccord Genuity initiated coverage on Morphic with a new price target
$MORF
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity initiated coverage of Morphic with a rating of Buy and set a new price target of $68.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $46.00 | Buy | Citigroup |
| 9/25/2023 | $61.00 → $33.00 | Hold | Stifel |
| 9/25/2023 | Buy → Neutral | BTIG Research | |
| 8/9/2023 | $69.00 → $61.00 | Buy → Hold | Stifel |
| 9/7/2022 | $44.00 | Buy | Stifel |
| 7/20/2022 | $45.00 | Outperform | SVB Leerink |
| 3/31/2022 | $68.00 | Buy | Canaccord Genuity |
| 2/25/2022 | $82.00 → $76.00 | Outperform | RBC Capital |
Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Morphic Holding, Inc. (NASDAQ:MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcera
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET. A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference. About Morphic TherapeuticMorphic
Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via
SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)
SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)
SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. "Simon brings clinical development expe
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022. 2022 and Recent Corporate H
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs. Ms. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences. "Joanne arrives at Morphic at a promising time. We are advancing clinical and pre-clinical integrin inhibitors generated by the MInT Platform and Joanne brings successful leadership experience across the full spectrum of regulatory affairs from preclinical activities through drug commer
4 - Morphic Holding, Inc. (0001679363) (Issuer)
4 - Morphic Holding, Inc. (0001679363) (Issuer)
Citigroup initiated coverage of Morphic with a rating of Buy and set a new price target of $46.00
Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously
BTIG Research downgraded Morphic from Buy to Neutral
4 - Morphic Holding, Inc. (0001679363) (Issuer)
4 - Morphic Holding, Inc. (0001679363) (Issuer)
4 - Morphic Holding, Inc. (0001679363) (Issuer)
15-12G - Morphic Holding, Inc. (0001679363) (Filer)
S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)
Stifel analyst Alex Thompson maintains Morphic Holding (NASDAQ:MORF) with a Hold and raises the price target from $30 to $57.
The Russell 2000 index of small caps, tracked by the iShares Russell 2000 ETF (NYSE:IWM), recorded its best weekly performance since October 2023, surging over 6% and reaching its highest level since January 2022. The rally was largely driven by Thursday’s session, where the Russell 2000 posted a remarkable 3.6% daily gain. This spike followed lower-than-expected June inflation data, which fueled speculation of potential interest rate cuts. However, Quincy Krosby, chief global strategist for LPL Financial, advises caution, suggesting that Russell 2000’s rate cut message may be “clouded by Fed’s concerns over labor market.” Krosby thinks a weaker labor market would still hurt the eco
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Lead asset MORF-057 is a small-molecule inhibitor of α4β7 that is currently in Phase 2b trial for ulcerative colitis (UC), with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn’s disease (CD). Also Read: Eli Lilly’s Alzheimer’s Therapy’s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst. Goldman Sachs writes that α4β7 is a clinically validated target in inflammatory bowel disease (IBD), as it notes Takeda Pharmaceutical Company Ltd’s (NYSE:TAK) Entyvio, a mAb tar